Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)

Study Overview
=================
Brief Summary
-----------------
The aim of this open, controlled, multicentre biomedical research study is to identify new markers specifically associated with Horton's disease. This would make it possible to improve the diagnosis and management of this disease. Participation consists in taking one or several blood samples depending on the group patients/controls.

Official Title
-----------------
Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)

Conditions
-----------------
Infectious Disease, Neoplasia, Solid Tumor, Hemopathy, Horton's Disease

Intervention / Treatment
-----------------
* Other: 1 blood sample
* Other: 2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients Patients who have provided written informed consent Patients with national health insurance cover Age: 50 to 90 years Patients with Horton' s disease : at the diagnosis, before any treatment or in remission or in relapse Patients with an infectious disease : Bacteriologically or radiologically confirmed Presenting an inflammatory syndrome defined by : CRP ≥ 10 mg / L and Fibrinogen ≥ 4 g / L or ESR ≥ 30 mm at H1 Patients with neoplasia ( solid tumour or hemopathy ) : At the diagnosis, before treatment by chemotherapy Presenting an inflammatory syndrome defined by: CRP ≥ 10 mg / L and Fibrinogen ≥ 4 g / L or ESR ≥ 30 mm at H1 Controls : These are healthy volunteers recruited among blood donators at Dijon CHU, voluntary hospital personnel ( nurses, doctors and secretaries ), patients at the EPHAD ( Champmaillot centre for geriatric patients ) and patients without infectious, inflammatory, or auto-immune disease ( CRP < 5mg / L ) or cancer recruited from the investigating departments of Dijon CHU. They will be matched for age and sex. Age: 18 - 90 years Patients with national health insurance cover who have provided written informed consent Absence of an inflammatory syndrome ( CRP < 5 mg / L ) Exclusion Criteria : Any patient who does not meet the inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Horton's disease<br> | Other: 2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)<br> <br> |
| Infectious disease<br> | Other: 1 blood sample<br> <br> |
| Neoplasia<br> | Other: 1 blood sample<br> <br> |
| Control<br> | Other: 1 blood sample<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantification of specific cytokines of the Th17 immune response (IL-17 A and IL-23) in the serum |  | Up to 6 months | 
| Quantification of LTh17 by flow cytometry |  | Up to 6 months | 
| Measurement of the activation level of genes specifically involved in Th17 response using RT-PCR on frozen mRNA |  | Up to 6 months | 
| Measure the ability of Treg to proliferate and to synthesize IL-17 in response to different antigenic stimulations |  | Up to 6 months |